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Introduction: The most common mechanism underlying overexpres-
sion and activation of anaplastic lymphoma kinase (ALK) in non–
small-cell lung carcinoma could be attributed to the formation of a 
fusion protein. To date, five fusion partners of ALK have been reported, 
namely, echinoderm microtubule associated protein like 4, tropomyo-
sin-related kinase-fused gene, kinesin family member 5B, kinesin light 
chain 1, and protein tyrosine phosphatase, nonreceptor type 3.
Methods: In this article, we report a novel fusion gene huntingtin inter-
acting protein 1 (HIP1)–ALK, which is conjoined between the hunting-
tin-interacting protein 1 gene HIP1 and ALK. Reverse-transcriptase 
polymerase chain reaction and immunohistochemical analysis were 
used to detect this fusion gene’s transcript and protein expression, 
respectively. We had amplified the full-length cDNA sequence of this 
novel fusion gene by using 5'-rapid amplification of cDNA ends. The 
causative genomic translocation t(2;7)(p23;q11.23) for generating this 
novel fusion gene was verified by using genomic sequencing. 
Results: The examined adenocarcinoma showed predominant acinar 
pattern, and ALK immunostaining was localized to the cytoplasm, 
with intense staining in the submembrane region. In break-apart, 
fluorescence in situ hybridization analysis for ALK, split of the 5' 
and 3' probe signals, and isolated 3' signals were observed. Reverse-
transcriptase polymerase chain reaction revealed that the tumor har-
bored a novel fusion transcript in which exon 21 of HIP1 was fused 
to exon 20 of ALK in-frame.
Conclusion: The novel fusion gene and its protein HIP1–ALK har-
boring epsin N-terminal homology, coiled-coil, juxtamembrane, and 
kinase domains, which could play a role in carcinogenesis, could 
become diagnostic and therapeutic target of the lung adenocarci-
noma and deserve a further study in the future.
Key Words: Lung cancer, Anaplastic lymphoma kinase, HIP1, 
Translocation.
(J Thorac Oncol. 2014;9: 419–422)
Anaplastic lymphoma kinase (ALK)–positive non– small-cell lung carcinoma (NSCLC) is highly sensitive to ALK kinase 
inhibitors such as crizotinib.1 More than 20 variants of the 
EML4–ALK fusion gene have been identified along with diver-
sity in the breakpoint and length of EML4.2 In addition, four 
more fusion partner genes of ALK have been identified: TRK-
fused gene, kinesin family member 5B (KIF5B), kinesin light 
chain 1, and protein tyrosine phosphatase, nonreceptor type3.3–6 
In the current study, we identified the aberrant expression of 
huntingtin interacting protein 1 (HIP1)-ALK and the chromo-
somal translocation for generating this fusion gene in NSCLCs.
CASE DESCRIPTION
A 38-year-old Korean woman with a nonsmoking history 
underwent lobectomy because of an irregular mass on the lingual 
division of the upper-left lobe (Fig. 1A). The tumor area measured 
2.5 × 2.5 cm2 and microscopic examination revealed an adenocar-
cinoma with predominant acinar pattern (Fig. 1C). Metastasis of 
one of nine lymph nodes was noticed. Immunohistochemistry 
showed that ALK (dilution 1:50; clone 5A4, Novocastra, 
Newcastle, United Kingdom) localized to the cytoplasm, with 
higher density in the submembrane region of tumor cells (Fig. 1D 
and E). In break-apart, fluorescence in situ hybridization analy-
sis for ALK (Abbott Molecular, Abbott Park, IL), split of the 5' 
and 3' probe signals and isolated 3' signals were observed (Fig. 
1B), confirming the chromosomal rearrangement. The tumor did 
not harbor either epidermal growth factor receptor (EGFR) or 
Kirsten rat sarcoma viral oncogene homolog (KRAS) mutations.
By using total RNA extracted from tumor tissue obtained 
from the patient, we had prepared a first-strand cDNA library 
by reverse-transcriptase polymerase chain reaction (PCR) to 
screen fusion transcripts involving ALK as a fusion partner. 
Then, we amplified a double-strand cDNA fragment for the 
fusion region of HIP1–ALK transcript by PCR using specific 
primers and the first-strand cDNA library. The SMARTer 
5'-rapid amplification of cDNA ends cDNA Amplification Kit 
(Clontech Laboratories, Inc., Mountain View, CA) was used to 
amplify the full-length cDNA of this novel fusion gene HIP1–
ALK. Then, the PCR products were cloned into the pCR4-
TOPO vector using the TOPO TA Cloning Kit (Invitrogen, 
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Carlsbad, CA) for DNA sequencing. The sequence analysis of 
HIP1–ALK cDNA showed that exon 21 of HIP1 was fused to 
exon 20 of ALK in-frame, generating a fusion mRNA harbor-
ing an intact 3762-base pair open reading frame encoding a 
deduced 1253-amino acid protein sequence that contains epsin 
N-terminal homology, coiled-coil, juxtamembrane, and kinase 
domains (Fig. 2A and B). The cDNA sequence of the novel 
fusion gene HIP1–ALK has been deposited in the National 
Center for Biotechnology Information database (accession 
number KF360988). Direct sequencing of genomic DNA 
also revealed that the genomic breakpoint occurred between 
79th nucleotide of intron 21 of HIP1 and 1017th nucleotide 
upstream from the nucleotide before the beginning nucleo-
tide of the exon 20 of ALK, thereby resulting in a chromo-
somal translocation t(2;7)(p23;q11.23) (Fig. 2A). Noticeably, 
the beginning nucleotide of this novel fusion gene’s 5'UTR 
was 127,263-base pair far away from the beginning nucleo-
tide of 5'UTR of reference gene HIP1 (NM_001243198.1) 
in the University of California, Santa Cruz (UCSC) Genome 
Browser. To check whether the 5'UTR of this novel fusion 
gene, which had been identified by our 5'-rapid amplification 
of cDNA ends in this study, could be very close to another pro-
moter which is different from the previously known one of the 
HIP1 reference gene (NM_001243198.1), we had searched 
ChIP-Seq database in the UCSC Genome Browser. Very 
interestingly, H3K4me3 signal, which could provide strong 
evidence for existence of a promoter region, appeared exactly 
around the beginning part of the 5'UTR of the fusion gene 
(Fig. 3A), confirming that HIP1–ALK could be regulated by 
not the conventional promoter of HIP1 but a novel promoter. 
The existence of this novel promoter could have been sub-
stantiated once more by our discovery in this study of a new 
HIP1 transcript variant (in submission process to National 
Center for Biotechnology Information) whose transcription 
starts from the same genomic nucleotide position as the first 
5' nucleotide position of the HIP1–ALK and ends at the 3'UTR 
of the HIP1 (Fig. 3B), implying that HIP1–ALK and the new 
HIP1 variant gene could be regulated by the novel promoter.
The binding site (755–783 in HIP1–ALK amino 
acid sequence) for crizotinib, which is an adenosine tri-
phosphate (ATP)-binding site in a normal condition, 
resides behind the breakpoint just after 691th amino acid, 
FIGURE 1. A, An irregular-shaped mass (red arrow) adjacent to the pleura revealed by chest computed tomography. B, 
Fluorescence in situ hybridization assay of ALK rearrangement revealed individual 3'-signals, indicating a chromosomal transloca-
tion event. C, Histology of HIP1–ALK–positive lung adenocarcinoma. Hematoxylin and eosin staining shows adenocarcinoma with 
predominant acinar pattern. D, E On ALK immunohistochemistry, the tumor cells were stained in the cytoplasm, showing densely 
stained submembrane region (D, ×100, E, ×200). ALK, anaplastic lymphoma kinase; HIP1, huntingtin interacting protein 1.
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participating in ALK part in the fusion protein HIP1–ALK 
and also strongly suggesting that HIP1–ALK activity could 
be inhibited by crizotinib.
The patient was treated with crizotinib according to 
the National Comprehensive Cancer Network guideline, 
which recommends crizotinib as a first-line therapy for 
locally advanced or metastatic ALK-positive NSCLC. 
After 15 months of follow-up, computed tomography scans 
did not reveal any evidence of recurrence or metastasis in 
the patient.
A
B FIGURE 2. A, Sequence analysis 
of the region fused between HIP1 
and ALK in genome and transcript 
level. B, Functional domain analysis 
of HIP1, ALK, and HIP1–ALK protein 
sequences. ALK, anaplastic lymphoma 
kinase; ENTH, epsin N-terminal 
homology; HIP1, huntingtin interact-
ing protein 1; JM, juxtamembrane.
HIP1 (NM_001243198.1)
HIP1 (NM_005338.5)
HIP1-ALK fusion transcript’s first 5’ part
HIP1 transcript variant’s first 5’ part
ENCODE Promoter-Associated Histone Mark (H3K4me3)
HIP1 (NM_001243198.1)
New HIP1 transcript variant
HIP1 (NM_005338.5)
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FIGURE 3. A, A novel promoter region (indicated by green mountain signal) for the novel fusion gene HIP1–ALK and a new HIP1 
transcript variant revealed by an ENCODE promoter-associated ChIP-Seq mark (H3K4me3) in the UCSC genome database. The dif-
ferent colors indicate that this promoter-associated histone mark landscape (for H3K4me3) had been established in the following 
cells; Gm12878 cells (red), H1 cells (orange), HepG2 cells (light green), HMEC cells (dense green), HSMM cells (light blue), HUVEC 
cells (blue), K562 cells (purple), NHEK cells (dense pink) and NHLF cells (pink). The higher the height of the peak is, the higher 
a probability of the peak site to become an H3K4me3 site (in other word, a potential promoter region) is. When the fusion gene 
HIP1–ALK and HIP1 novel variant had been transcribed, a novel exonization (for the first exon of HIP1–ALK and HIP1 novel variant) 
occurred, creating a novel exon with a length of 37 base pair that is not present in HIP1 transcript. B, The new HIP1 gene variant 
lacking a majority of first intron sequence compared with those of the two HIP1 reference genes. ALK, anaplastic lymphoma kinase. 
ENCODE, The Encyclopedia of DNA Elements; HIP1, huntingtin interacting protein 1; HMEC, Human Mammary Epithelial Cells; 
HSMM, Human Skeletal Muscle Myoblasts; HUVEC, Human Umbilical Vein Endothelial Cells; NHEK, epidermal keratinocytes; NHLF, 
Normal Human Lung Fibroblasts; UCSC, University of California, Santa Cruz.
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DISCUSSION
This is the first report of a novel HIP1–ALK fusion gene 
in NSCLC. Kalchman et al.7 reported that HIP1 is essential for 
the membrane–cytoskeletal integrity in the brain. HIP1 plays 
an important role in clathrin trafficking and cell survival. The 
epsin N-terminal homology domain–containing protein binds 
to polyphosphoinositide-signaling lipids and has been found 
in cofactors of clathrin-mediated trafficking.8 HIP1 is over-
expressed in various human cancer cell lines, which indicates 
that HIP1 could provide a selective growth advantage to cancer 
cells. Among them, mRNA level of HIP1 increased in pros-
tate and colon cancer cell lines compared with that in normal 
epithelial cell lines of prostate and colon.9 The first descrip-
tion of chromosomal translocation of HIP1 in the pathogen-
esis had come out from chronic myelomonocytic leukemia 
with  platelet-derived growth factor β receptor. HIP1– platelet-
derived growth factor β receptor fusion with t(5;7)(q33;q11.2) 
translocation may contribute to leukemogenesis and lead 
to transformation of hematopoietic cells.10 The HIP1–ALK 
fusion protein comprises the coiled-coil domain of HIP1 and 
the juxtamembrane intracellular region of ALK, which plays 
an important role in maintaining ALK kinase activity (Fig. 2B). 
Together with dimerization through the coiled-coil domain, the 
ALK tyrosine kinase activity of the fusion protein may be acti-
vated aberrantly, thus facilitating oncogenesis in the lung.11,12 
Although further studies are needed to ascertain the transform-
ing properties of this HIP1–ALK fusion protein in cellular and 
mouse models, it is likely that this novel fusion protein also may 
harbor transforming activities from its chimeric protein struc-
ture. Takeuchi et al.4 found a novel ALK fusion protein KIF5B–
ALK in lung cancer using an  immunohistochemistry-based 
diagnostic system. They suggested that the subcellular local-
ization of ALK fusion proteins probably depends on the fusion 
partner. Whereas nucleophosmin–ALK exhibits both nuclear 
and cytoplasmic staining, EML4–ALK stains in the cytoplasm, 
but not in the nucleus. The perinuclear halo pattern observed 
in KIF5B–ALK may indicate the accumulation of fusion pro-
tein at the periphery of the cytoplasm. In this case, the HIP1–
ALK staining pattern is similar to that of KIF5B–ALK, which 
resembles submembrane granular staining.
CONCLUSION
To the best of our knowledge, HIP1–ALK is the first 
novel fusion transcript reported in ALK-positive lung cancer. 
Given that the HIP1 protein contains coiled-coil domains, the 
fusion protein possibly dimerizes constitutively and, thereby, 
could possess a strong transforming potential.12 Patients with 
HIP1–ALK translocation may therefore respond to treatment 
with ALK inhibitors. This case report could provide novel 
diagnostic and therapeutic candidate target for patients with 
NSCLC.
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